Baff specific antibodies
IL328546A0Pending Publication Date: 2026-07-01GLAXOSMITHKLINE INTPROP DEV LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- IL328546
- Authority / Receiving Office
- IL · IL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-11
- Filing Date
- 2024-12-09
- Publication Date
- 2026-07-01
AI Technical Summary
Technical Problem
Current treatments for systemic lupus erythematosus (SLE) and lupus nephritis are inadequate, leading to irreversible organ damage and high mortality rates due to autoantibody production and B cell dysregulation.
Method used
Development of BLyS binding proteins, specifically monoclonal antibodies or antigen binding fragments, that selectively bind to BLyS, inhibiting its interaction with its receptors, thereby modulating B cell activity and reducing autoantibody production.
Benefits of technology
The BLyS binding proteins effectively decrease B cell proliferation and autoantibody production, potentially reducing disease activity, organ damage, and the need for steroids in SLE and lupus nephritis patients.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to anti-BLyS antigen binding proteins such as an anti-BLyS antibody which is capable of antagonizing BLyS. The invention also relates to nucleic acid sequences which encode the antigen binding protein as well as the use the antigen binding protein in therapy, for example, in diseases in which B cells play a pathogenic role, such as, for example, in autoimmune diseases, chronic inflammatory diseases and / or cancer.
Need to check novelty before this filing date? Find Prior Art